#MedTech #Belgium #Leuven #miDiagnostics #Katleen Verleysen

miDiagnostics and CEO Katleen Verleysen Celebrate Recognition in Global Corporate Excellence

In a remarkable achievement, miDiagnostics, along with its CEO Katleen Verleysen, has been honored in the 2026 Global Corporate Excellence Awards organized by Business Worldwide Magazine. This prestigious event highlights the relentless pursuit of excellence in the corporate sector, acknowledging organizations that demonstrate innovation, ethical standards, and remarkable performance.

Recognition Highlights

miDiagnostics was awarded the title of ‘MedTech Company of the Year – Breakthrough Diagnostic Technology | Europe’. Concurrently, CEO Katleen Verleysen was recognized as ‘Outstanding Leadership in Clinical Molecular Diagnostics | Europe’. These accolades underscore the company's substantial contributions to the medical diagnostics field and the impactful leadership provided by Verleysen.

Based in Leuven, Belgium, miDiagnostics is dedicated to pioneering ultra-fast PCR-based testing technologies that significantly enhance the delivery of advanced immunotherapies, including CAR-T therapies for cancer treatment. The company’s innovative platform delivers sterility testing results in under two hours—a major advancement compared to traditional methods that typically take several days—allowing for faster treatment delivery without sacrificing safety or regulatory compliance.

The Importance of Innovation in Healthcare

As personalized medicine progressively reshapes the healthcare landscape, rapid and reliable testing technologies are ever more crucial. CAR-T therapies can do wonders for patients battling aggressive forms of cancer, yet they require specialized manufacturing processes and thorough sterility validations before treatment administration. Through its cutting-edge PCR technology, miDiagnostics adeptly addresses the problem of microbial contamination, ensuring that treatment can proceed without unnecessary delays.

Since taking the helm in 2021, Verleysen has been instrumental in expanding the company’s commercial footprint and positioning it within the ever-evolving life sciences sector. Verleysen’s strong background in chemistry and her strategic leadership approach have been pivotal in transforming miDiagnostics from a research-focused enterprise into an acclaimed medtech leader.

Under her guidance, the company has made significant strides in building a robust operational and commercial framework to support its global ambitions. miDiagnostics is now collaborating with several leading organizations, including major pharmaceutical companies, to explore and integrate rapid sterility testing solutions within advanced therapy manufacturing workflows.

Looking Ahead

The versatile technology developed by miDiagnostics not only aids oncology treatments but also promises significant potential across the broader spectrum of immunotherapy applications, encompassing various autoimmune and complex conditions where personalized medicine is anticipated to play a crucial role.

Commenting on the recent honors, Verleysen expressed her gratitude: “I am deeply honored by this recognition and proud of what our team has achieved together. At miDiagnostics, we believe innovation must ultimately benefit patients. This award reflects the scientific excellence, collaboration, and dedication of our team as we work tirelessly to deliver advanced therapies to patients around the world.”

In the last few years, both miDiagnostics and Katleen Verleysen have received numerous international accolades, including recognition as the Top MedTech Startup in Europe, European CEO of the Year for two consecutive years (2024 and 2025), and the title of Top Innovative Chief Executive Officer in Life Sciences at BIO-Europe 2025.

As the healthcare industry places increasing emphasis on quicker, smarter, and more tailored treatments, miDiagnostics is set to remain at the forefront of diagnostic innovation, enabling pharmaceutical partners to deliver advanced therapies to patients more effectively and swiftly than ever before.